CAR-T Meeting 2020 | Cost-effectiveness of CAR T-cell therapy

Carin Al Uyl-de Groot

Carin Al Uyl-de Groot, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands, discusses the evaluation of the cost-effectiveness of CAR T-cell therapy for pediatric acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter